Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...

Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...

NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity for private industry research, technology demonstrations, and more. Today, ...

The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.

ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg Updated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC ...

SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...

Discover comprehensive details about Pembrolizumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...